期刊
MOLECULAR THERAPY
卷 22, 期 5, 页码 901-907出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/mt.2014.6
关键词
-
资金
- Instituto de Salud Carlos III [PI12/00322]
- United Mitochondrial Disease Foundation [12-029]
- French Muscular Dystrophy Association-Telethon (AFMTelethon)
- Telethon-Italy [GPP10005, GGP11011]
- Cariplo [2011-0526]
- European Research Council [ERC-322424]
- Italian Ministry of Health Research Grant [GR-2010-2306-756]
- Pierfranco and Luisa Mariani Foundation Italy
- MRC [MC_UP_1002/1] Funding Source: UKRI
- Medical Research Council [MC_UP_1002/1] Funding Source: researchfish
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder caused by mutations in TYMP, enconding thymidine phosphorylase (TP). TP deficiency results in systemic accumulation of thymidine and deoxyuridine, which interferes with mitochondria! DNA (mtDNA) replication and leads to mitochondrial dysfunction. To date, the only treatment available for MNGIE patients is allogeneic hematopoietic stem cell transplantation, which is associated with high morbidity and mortality. Here, we report that AAV2/8-mediated transfer of the human TYMP coding sequence (hcTYMP) under the control of a liver-specific promoter prevents the biochemical imbalances in a murine model of MNGIE. hcTYMP expression was restricted to liver, and a dose as low as 2x10(11) genome copies/kg led to a permanent reduction in systemic nucleoside levels to normal values in about 50% of treated mice. Higher doses resulted in reductions to normal or slightly below normal levels in virtually all mice treated. The nucleoside reduction achieved by this treatment prevented deoxycytidine triphosphate (dCTP) depletion, which is the limiting factor affecting mtDNA replication in this disease. These results demonstrate that the use of MV to direct TYMP expression in liver is feasible as a potentially safe gene therapy strategy for MNGIE.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据